Micafungin Biocon

Micafungin, the active ingredient in Micafungin Biocon, is an Echinocandin presented as an intravenous formulation for infusion use. It is employed to treat invasive candidiasis, esophageal candidiasis, and to provide prophylaxis against Candida infections in patients undergoing hematopoietic stem cell transplantation.

GNH USA supplies Micafungin Biocon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and oncology centres worldwide.

Micafungin is an echinocandin antifungal that targets invasive fungal infections and prophylactic needs in high‑risk patients.

- Invasive candidiasis: eradicates bloodstream and deep‑tissue Candida infections. - Esophageal candidiasis: clears mucosal Candida overgrowth in the esophagus. - Prophylaxis in hematopoietic stem cell transplantation: prevents Candida infection during periods of severe immunosuppression.

Micafungin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Elevated liver enzymes: transient increase in ALT or AST. - Fever: mild to moderate temperature rise. - Nausea: occasional gastrointestinal discomfort. - Headache: mild, self‑limiting.

Serious or Rare Side Effects: - Hepatotoxicity: significant liver injury requiring monitoring. - Severe hypersensitivity: rash, angioedema, or anaphylaxis. - Infusion‑related reactions: hypotension, dyspnea, or chest discomfort.

Before initiating Micafungin therapy, clinicians should consider several safety measures.

- Liver function monitoring: assess baseline enzymes and repeat during treatment. - Renal function assessment: adjust use in severe renal impairment if needed. - Concomitant hepatotoxic drugs: avoid or monitor closely. - Pregnancy and lactation: weigh potential benefits against unknown risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin): may reduce micafungin exposure. - Highly protein‑bound drugs (e.g., warfarin): potential displacement increasing free drug levels.

Moderate Interactions (Monitor Closely): - Azole antifungals (e.g., fluconazole): may increase micafungin concentrations. - Immunosuppressants (e.g., tacrolimus): monitor levels for possible elevation.